New Hope for Breast Cancer Patients: Hetero Healthcare and Enzene Biosciences Launch India's Most Affordable Pertuzumab
Hyderabad (The Uttam Hindu): In a strategic step to democratise access to advanced cancer therapies, Hetero Healthcare Ltd., one of India’s leading pharmaceutical companies, has announced the launch of Perzea, its most affordable biosimilar of Pertuzumab. The product, a targeted therapy for HER2-positive breast cancer, has been introduced through a semi-exclusive collaboration with Enzene Biosciences Ltd.
This partnership reinforces Hetero Healthcare’s commitment to making high-quality oncology therapies accessible and affordable for patients across India, while aligning with the Government of India’s healthcare vision to ensure equitable access to life-saving medications.
Bridging the Treatment Gap
Pertuzumab, a monoclonal antibody, is globally recognised as a standard of care when used in combination with trastuzumab and chemotherapy for treating HER2-positive breast cancer. With the launch of Perzea, Hetero Healthcare seeks to reduce cost barriers, enabling thousands of patients in India to access advanced treatment options and improving overall outcomes.
Leadership Commentary
Mr. M. Srinivas Reddy, Managing Director, Hetero Healthcare Ltd., said:
“At Hetero Healthcare, our focus has always been on innovation and affordability. The launch of Perzea, in collaboration with Enzene Biosciences, highlights our commitment to bringing world-class cancer therapies within reach of Indian patients.”
Dr. Himanshu Gadgil, CEO, Enzene Biosciences, added:
“We are proud to partner with Hetero Healthcare in this impactful endeavour. At Enzene, our mission is to leverage cutting-edge technology platforms to deliver high-quality biologics at affordable prices. This collaboration is a reflection of our shared vision to transform cancer care in India.”
About Hetero Healthcare
Hetero Healthcare Ltd. is a leading pharmaceutical company dedicated to delivering affordable, high-quality medicines across diverse therapeutic areas. With a strong presence in oncology, antiretrovirals, and critical care, Hetero Healthcare continues to expand its reach and innovate to improve patient outcomes across India.
About Enzene Biosciences
Enzene Biosciences Ltd., a subsidiary of Alkem Laboratories, is a biotechnology company specialising in biosimilars, novel biologics, and complex injectables. With state-of-the-art manufacturing facilities and a strong focus on innovation, Enzene is committed to enhancing access to advanced biologic therapies globally.